A groundbreaking medical breakthrough has given a 66-year-old man with end-stage kidney disease a second chance at life. Tim Andrews, from Massachusetts, underwent an experimental transplant using a genetically modified pig kidney. The procedure, facilitated by the US Food and Drug Administration’s Expanded Access pathway, marks a significant milestone in the field of xenotransplantation.
Andrews had been on dialysis for two years due to his rare blood type, which made it difficult to find a compatible donor organ. His chances of living five more years on long-term dialysis were estimated at just 35%. However, after being offered an opportunity to receive the pig kidney, Andrews felt a sense of hope and renewal.
The pig kidney transplant was conducted by doctors at Massachusetts General Hospital using an organ developed by eGenesis. The procedure was successful, with Andrews expected to continue receiving close monitoring and follow-up care.
This breakthrough has been hailed as a major turning point in the field of transplantation. United Therapeutics, another biotech company, recently announced its approval to move forward with xenotransplant trials for its pig kidneys, which have 10 gene edits.
Experts believe that xenotransplantation holds great promise for thousands of patients suffering from end-stage kidney disease. With an estimated 37 million adults in the US experiencing chronic kidney disease, this innovative solution offers a glimmer of hope for those who have been waiting on organ transplant lists.
Andrews’ story serves as a testament to the power of human resilience and the importance of continued medical research. As he embarks on his new life with the pig kidney transplant, Andrews is determined to make the most of this second chance and inspire others in need.
Source: https://edition.cnn.com/2025/02/07/health/pig-kidney-transplant-clinical-trials/index.html